| MeSH term | MeSH ID | Detail |
|---|---|---|
| Myelitis | D009187 | 1 associated lipids |
| Erythroplasia | D004919 | 1 associated lipids |
| Migraine with Aura | D020325 | 1 associated lipids |
| Hutchinson's Melanotic Freckle | D018327 | 2 associated lipids |
| Lacerations | D022125 | 1 associated lipids |
| Trauma, Nervous System | D020196 | 2 associated lipids |
| Central Nervous System Viral Diseases | D020805 | 1 associated lipids |
| Neuroaspergillosis | D020953 | 2 associated lipids |
| Hepatopulmonary Syndrome | D020065 | 1 associated lipids |
| Arm Injuries | D001134 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Blackham A and Griffiths RJ | The effect of FK506 and cyclosporin A on antigen-induced arthritis. | 1991 | Clin. Exp. Immunol. | pmid:1718639 |
| Carobbi A et al. | Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. | 1991 | Transplant. Proc. | pmid:1703704 |
| Jain AB et al. | Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. | 1991 | Transplant. Proc. | pmid:1721274 |
| McMichael J et al. | Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721275 |
| Donnelly JG and Soldin SJ | Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721305 |
| Rosborough SL et al. | Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. | 1991 | Transplant. Proc. | pmid:1721306 |
| Zeevi A et al. | In vitro assessment of FK 506 immunosuppressive activity in transplant patients. | 1991 | Transplant. Proc. | pmid:1721307 |
| Shaw BW et al. | FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. | 1991 | Transplant. Proc. | pmid:1721338 |
| McDiarmid SV et al. | FK 506 rescue therapy in liver transplantation: outcome and complications. | 1991 | Transplant. Proc. | pmid:1721339 |
| Gordon RD et al. | Liver transplantation under cyclosporine: a decade of experience. | 1991 | Transplant. Proc. | pmid:1703339 |
| Todo S et al. | One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. | 1991 | Transplant. Proc. | pmid:1703340 |
| Fries D et al. | Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. | 1991 | Transplant. Proc. | pmid:1721370 |
| Wijnen RM et al. | Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. | 1991 | Transplant. Proc. | pmid:1721371 |
| Lopez OL et al. | Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721400 |
| Viebahn R et al. | Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721401 |
| Morrisett JD et al. | Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. | 1991 | Transplant. Proc. | pmid:1721402 |
| de Paulis A et al. | FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. | 1991 | J. Immunol. | pmid:1706398 |
| Griffiths EJ and Halestrap AP | Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. | 1991 | Biochem. J. | pmid:1706598 |
| Wu GD et al. | FK 506 inhibits the development of transplant arteriosclerosis. | 1991 | Transplant. Proc. | pmid:1721433 |
| Kobayashi N et al. | Effect of FK 506 on abdominal organ cluster transplantation in pigs. | 1991 | Transplant. Proc. | pmid:1721434 |
| McAlpine JB et al. | Revised NMR assignments for rapamycin. | 1991 | J. Antibiot. | pmid:1712766 |
| Banerji SS et al. | The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. | 1991 | Mol. Cell. Biol. | pmid:1712901 |
| Staruch MJ et al. | Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. | 1991 | Int. J. Immunopharmacol. | pmid:1721613 |
| Matsuura T et al. | [Experimental studies on the mode of action of cyclosporine and FK506 assessed by proliferation response of human cloned T lymphocytes]. | 1991 | Hinyokika Kiyo | pmid:1721767 |
| Nakahama H et al. | Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. | 1991 | J. Cardiovasc. Pharmacol. | pmid:1725322 |
| Romanowski P et al. | [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. | 1991 | Postepy Biochem. | pmid:1725924 |
| Jiang H et al. | Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. | 1991 | Transplant. Proc. | pmid:1703702 |
| Jordan ML et al. | Initial studies with FK506 in renal transplantation. | 1991 Sep-Oct | Cleve Clin J Med | pmid:1718631 |
| Stangl MJ et al. | The use of FK506 and RS61443 for reversal of small-bowel rejection. | 1992 | Transpl. Int. | pmid:14621800 |
| Wijnen RM et al. | Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. | 1992 | Transpl. Int. | pmid:14621844 |
| Jiang H et al. | Control of humoral and cellular immunity-mediated accelerated heart allograft rejection in sensitized rats by low dose FK 506 and splenectomy. | 1992 | Transpl. Int. | pmid:14621859 |
| Kobayashi N et al. | Abdominal organ cluster transplantation in pigs and FK506. | 1992 | Transpl. Int. | pmid:14621861 |
| Hanawa H et al. | An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats. | 1992 | Clin. Immunol. Immunopathol. | pmid:1371730 |
| Hiraoka Y et al. | The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis. | 1992 | J. Pharmacol. Exp. Ther. | pmid:1372051 |
| Chen TS et al. | Microbial transformation of immunosuppressive compounds. I. Desmethylation of FK506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. | 1992 | J. Antibiot. | pmid:1372307 |
| Sigal NH and Dumont FJ | Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. | 1992 | Annu. Rev. Immunol. | pmid:1375473 |
| Demetris AJ et al. | Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. | 1992 | Lancet | pmid:1376851 |
| Ichihashi T et al. | Haemolytic uraemic syndrome during FK506 therapy. | 1992 | Lancet | pmid:1376852 |
| O'Keefe SJ et al. | FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. | 1992 | Nature | pmid:1377361 |
| DiLella AG et al. | Chromosomal band assignments of the genes encoding human FKBP12 and FKBP13. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1281998 |
| Sawada M et al. | Down regulation of CD4 expression in cultured microglia by immunosuppressants and lipopolysaccharide. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1282000 |
| Minoda M et al. | Effects of gamma-interferon and FK506 on resting B cell proliferation of New Zealand black/white F1 mice. | 1992 | Microbiol. Immunol. | pmid:1282197 |
| Yoshimura R et al. | A comparative study of cyclosporine vs FK 506: role of kidney microsomal cytochrome P-450. | 1992 | Transplant. Proc. | pmid:1379755 |
| Yamada K et al. | FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney--morphologic and biologic analysis. | 1992 | Transplant. Proc. | pmid:1379756 |
| Fukuse T et al. | Optimal dose of FK 506 in canine lung allotransplantation. | 1992 | Transplant. Proc. | pmid:1379757 |
| Wada H et al. | Combination use of suboptimal doses of FK 506 and cyclosporine in canine lung transplantation. | 1992 | Transplant. Proc. | pmid:1379758 |
| Karpas A et al. | Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. | 1992 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1381509 |
| Yatscoff RW and Shaw LM | Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. | 1992 | Ther Drug Monit | pmid:1381530 |
| Arceci RJ et al. | Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. | 1992 | Blood | pmid:1381629 |
| Mochizuki M et al. | Preclinical and clinical study of FK506 in uveitis. | 1992 | Curr. Eye Res. | pmid:1385045 |